[
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
    "title": "Kvartalsrapport Q1 2026",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a6942a777fa930bf7ba2a66e9c6e7d709",
    "date": "2026-04-29",
    "period": "2026-q1",
    "form_type": "interim-report",
    "report_key": "2026:q1",
    "filename": "Q1_2026_Report_SE_Final_29Apr26.pdf",
    "text_chars": 46392,
    "sha256": "ff9f5cc745ae70cf8c049a2abd6c76b101978569d7298748622e6f886ff4f589",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
        "chars": 46392
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2025",
    "title": "Årsredovisning 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a206b29851971e83a5e68d755cca5175a",
    "date": "2026-03-24",
    "period": "2025-annual",
    "form_type": "annual-report",
    "report_key": "2025:annual",
    "filename": "SE_Egetis_Arsredovisning_2025_Final.pdf",
    "text_chars": 315393,
    "sha256": "206190893364d309d49e76354c86f46872e1ddc1eda7ff77c2d41d92821021f9",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
        "chars": 176425
      },
      {
        "number": 2,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
        "chars": 138966
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
    "title": "Kvartalsrapport Q4 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/afb4ad5faeb596fcdd65881be25fbee53",
    "date": "2026-02-26",
    "period": "2025-q4",
    "form_type": "year-end-report",
    "report_key": "2025:q4",
    "filename": "Q4_2025_Report_SE_Final_26Feb26.pdf",
    "text_chars": 49800,
    "sha256": "1bde4c42b0bb53c1c079966ee502f2bfe91ba95d1277103e83b2ac60b2c45362",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
        "chars": 49800
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
    "title": "Kvartalsrapport Q3 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/abb89c7e3bfb497221a55896c76316fd4",
    "date": "2025-11-25",
    "period": "2025-q3",
    "form_type": "interim-report",
    "report_key": "2025:q3",
    "filename": "Q3_2025_Report_SE_Final_251125.pdf",
    "text_chars": 50087,
    "sha256": "b49416f6b530d87e6fa92f0709ba4418aa8f662bf4d10ce866e085ae271edc8f",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
        "chars": 50087
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
    "title": "Kvartalsrapport Q2 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ac44f8c6ae3726c1abdc80e5151a80988",
    "date": "2025-08-21",
    "period": "2025-q2",
    "form_type": "interim-report",
    "report_key": "2025:q2",
    "filename": "Q2_2025_Report_SE_21Aug25_Final2.pdf",
    "text_chars": 9423,
    "sha256": "1c00dfb9aa39bd12a0d6a12a54d34af3bd191f6215f3fadd5c09216425e94ed0",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
        "chars": 9423
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
    "title": "Kvartalsrapport Q1 2025",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://storage.mfn.se/6c145720-d2d9-4d4e-a1d2-0c306524c482/se-egetis-arsredovisning-2024-final-11apr24.pdf",
    "date": "2025-04-30",
    "period": "2025-q1",
    "form_type": "interim-report",
    "report_key": "2025:q1",
    "filename": "se-egetis-arsredovisning-2024-final-11apr24.pdf",
    "text_chars": 322374,
    "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
        "chars": 177753
      },
      {
        "number": 2,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-002.html",
        "chars": 144619
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2024",
    "title": "Årsredovisning 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a46c706f2daf09ea8e3384d4049251d6f",
    "date": "2025-04-11",
    "period": "2024-annual",
    "form_type": "annual-report",
    "report_key": "2024:annual",
    "filename": "SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf",
    "text_chars": 322374,
    "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
        "chars": 177753
      },
      {
        "number": 2,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
        "chars": 144619
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
    "title": "Kvartalsrapport Q4 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ae9ee14b96c878a9a47db936acdbb5aa3",
    "date": "2025-02-26",
    "period": "2024-q4",
    "form_type": "year-end-report",
    "report_key": "2024:q4",
    "filename": "Q4_2024_Report_SE_26Feb25_FINAL.pdf",
    "text_chars": 60074,
    "sha256": "7a4a10a1d1c6c88068236b0ffa80bd9650e4cae88f80b5c1a62e4ba8e0e5f6d3",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
        "chars": 60074
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
    "title": "Kvartalsrapport Q3 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a00e566ae0ea10c2f34e55f9ae3dbfc07",
    "date": "2024-11-08",
    "period": "2024-q3",
    "form_type": "interim-report",
    "report_key": "2024:q3",
    "filename": "Q3_2024_Report_SE_08Nov24_Final.pdf",
    "text_chars": 63859,
    "sha256": "a1a8d360bc3da5e4da946ec8c2702fde4f5eeb447605dd895ed6f93c7a7383f1",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
        "chars": 63859
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
    "title": "Kvartalsrapport Q2 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/ad971c0227867ee160499400f812e4bc1",
    "date": "2024-08-22",
    "period": "2024-q2",
    "form_type": "interim-report",
    "report_key": "2024:q2",
    "filename": "Q2_2024_Report_SE_240822_Final.pdf",
    "text_chars": 11615,
    "sha256": "51e1b382f5a02633c6cfe88c874df8987bf950c55b1a47f1ff17d3eedb18e663",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
        "chars": 11615
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
    "title": "Kvartalsrapport Q1 2024",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/abd668147eaa3e410da42161261df85bc",
    "date": "2024-05-03",
    "period": "2024-q1",
    "form_type": "interim-report",
    "report_key": "2024:q1",
    "filename": "Q1_2024_Report_SE_240502_Final3.pdf",
    "text_chars": 18247,
    "sha256": "579b9bc37fc30053cc5539be29354a48a33bfbc0341d9e37ee3c4d79e11eaaae",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
        "chars": 18247
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-arsredovisning-2023",
    "title": "Årsredovisning 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/af3cbeb2a13b2252df08cedc14f66f84e",
    "date": "2024-04-15",
    "period": "2023-annual",
    "form_type": "annual-report",
    "report_key": "2023:annual",
    "filename": "SE_Egetis_Arsredovisning_2023_15apr_Final.pdf",
    "text_chars": 318947,
    "sha256": "c13ece608fcfbaf3d8bdc4f7c9d4b18ab9bdbcd5a2816c389909574d7516621b",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
        "chars": 176539
      },
      {
        "number": 2,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
        "chars": 142406
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
    "title": "Kvartalsrapport Q4 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a12a7619ddbbcdd6dbc09b8b68c4559b6",
    "date": "2024-02-22",
    "period": "2023-q4",
    "form_type": "year-end-report",
    "report_key": "2023:q4",
    "filename": "Q4_2023_Report_SE_22Feb24_Final.pdf",
    "text_chars": 12027,
    "sha256": "c74b0310aa944a883fbfde5f82b17babc92c1a2544b19825afe7c951fa796187",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
        "chars": 12027
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
    "title": "Kvartalsrapport Q3 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/af10655b0f42a9aca5c888135b38d3696",
    "date": "2023-11-08",
    "period": "2023-q3",
    "form_type": "interim-report",
    "report_key": "2023:q3",
    "filename": "Q3_2023_Report_SE_231108_Final.pdf",
    "text_chars": 14617,
    "sha256": "6b974f7a141056849b25d4455bd5a97735ff5a76dd998261d1efdb488ac1bd86",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
        "chars": 14617
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
    "title": "Kvartalsrapport Q2 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a7bfb1997a92a6956a70d8d6fec6bdca2",
    "date": "2023-08-22",
    "period": "2023-q2",
    "form_type": "interim-report",
    "report_key": "2023:q2",
    "filename": "Q2_2023_Report_SE_2023_08_22_Final.pdf",
    "text_chars": 12420,
    "sha256": "bb0886b68a2e034010940ab25a0ffc98402fc63c1f316c59cfb58a860ff10a0c",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
        "chars": 12420
      }
    ]
  },
  {
    "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
    "title": "Kvartalsrapport Q1 2023",
    "source": "Nasdaq Nordic",
    "source_class": "nasdaq-report",
    "source_url": "https://attachment.news.eu.nasdaq.com/a54a3c90b056400d051dbf7b09b8f0182",
    "date": "2023-04-26",
    "period": "2023-q1",
    "form_type": "interim-report",
    "report_key": "2023:q1",
    "filename": "Q1_2023_Report_SE_26Apr23_FINAL.pdf",
    "text_chars": 11347,
    "sha256": "7bd65deddf5154ea59d06116f0426bab167e1bec38b054a309421d852aabbe0c",
    "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
    "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
        "chars": 11347
      }
    ]
  },
  {
    "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
    "title": "MFN bolagssida och bolagsmetadata",
    "source": "MFN",
    "source_class": "mfn",
    "source_url": "https://mfn.se/all/a/egetis-therapeutics",
    "date": null,
    "period": null,
    "form_type": "company-page",
    "report_key": null,
    "filename": "company.txt",
    "text_chars": 14359,
    "sha256": "62dde7ee36b2003d474e4d63ec3d16f38c2a64ed2f14f5a1ac92cf4297e44733",
    "url": "/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
    "txt_url": "/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
    "parts": [
      {
        "number": 1,
        "url": "/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
        "chars": 14359
      }
    ]
  }
]